15 Years of Real-World Data Collection in Early Access Programs: From Innovation to Essential Capability
For more than a decade, Real-World Data (RWD) collection within Early Access Programs (EAPs) has attracted increasing attention across the pharmaceutical industry.
What was once considered a niche or experimental approach has now evolved into a core capability, essential to delivering value across clinical development, regulatory strategy, and patient access.
Table of Contents
From early experimentation to integrated solutions
The journey of RWD collection in EAPs has been one of rapid transformation. Early initiatives were often fragmented and technologically limited, relying on adapted systems and manual processes. Inceptua itself pioneered one of the first custom-built RWD collection systems within an EAP environment, laying the groundwork for what would become industry-standard practices.
Today, digital innovation has reshaped how EAPs operate. Modern online platforms now function as fully integrated Electronic Data Capture (EDC) systems, enabling seamless collection, management, and analysis of patient data alongside treatment delivery.
A key requirement is flexibility: programs must be able to support both simple supply-only models and more complex environments where data collection is critical. The ability to “toggle” advanced RWD features on or off ensures that each program can be tailored to regulatory requirements, sponsor objectives, and physician capacity.
The strategic value of RWD in Early Access
EAPs provide access to investigational or pre-commercial therapies for patients with serious or life-threatening conditions who lack alternative options. In doing so, they create a unique opportunity to generate insights into how treatments perform in real-world settings.
RWD collected through EAPs can:
- Enhance understanding of safety and efficacy in broader, more diverse patient populations
- Support regulatory submissions and label expansion decisions
- Inform health technology assessments (HTA) and reimbursement strategies
- Provide valuable evidence in rare diseases, where clinical trial populations are limited
For pharmaceutical and biotech companies, integrating RWD strategies into EAPs enables earlier access to meaningful insights – often before commercialization – helping shape both medical and commercial outcomes.
Regulatory and ethical considerations
Despite its clear value, RWD collection in EAPs exists within a complex regulatory landscape. Traditionally, EAPs have been positioned as treatment-only initiatives, not research activities. However, this distinction is increasingly being challenged.
There is a growing recognition that treating patients with unapproved therapies carries both an opportunity and a responsibility to collect data that can improve future care. Regulatory bodies such as the FDA and EMA are progressively encouraging the use of real-world evidence in decision-making, signaling a shift toward greater acceptance.
At the same time, companies must navigate:
- Country-specific regulations and data privacy frameworks
- Ethical considerations related to patient consent and burden
- The need to align data collection with routine clinical practice
Balancing these factors requires both expertise and adaptability – areas where experienced EAP partners play a critical role.
The challenge: Unlocking the full potential of EAP data
While thousands of patients are treated every year through EAPs, the systematic use of RWD remains underutilized.
Often, data is either not collected at all or captured inconsistently, limiting its ability to support meaningful insights. To address this gap, RWD must be considered from the earliest stages of program design.
Successful strategies include:
- Defining clear objectives (e.g., safety, efficacy, quality of life)
- Aligning stakeholders across clinical, regulatory, and commercial teams
- Limiting data points to reduce burden on physicians
- Embedding data collection into routine workflows
A proactive and structured approach ensures that RWD is not an afterthought – but a fundamental component of the program.
Inceptua’s perspective: Experience, Scale and Innovation
With extensive global experience in Early Access Programs, we have been at the forefront of integrating RWD collection into access strategies. We support pharmaceutical companies with:
- Strategic program design and regulatory navigation
- Digital infrastructure for seamless data capture
- Global operational execution across more than 120 countries
- End-to-end support, from planning through commercialization
By combining regulatory expertise, digital capabilities, and operational excellence, we enable sponsors to maximize both patient access and data value.
Looking ahead: RWD as a standard, not an Exception
The role of Real-World Data in Early Access Programs is no longer emerging -it is expected. As healthcare systems increasingly rely on real-world evidence, the importance of capturing high-quality, structured data from EAPs will only grow.
To fully realize this potential, the industry must continue to:
- Advocate for clearer and more consistent regulatory frameworks
- Invest in scalable, user-friendly digital platforms
- Promote collaboration across stakeholders
- Recognize the ethical imperative of learning from every treated patient
Early access is no longer a peripheral activity – it is a strategic pillar of drug development and launch. And within it, Real-World Data is one of the most powerful tools available to improve patient outcomes and accelerate innovation.
You might be wondering the relevance of the photo at the top? I opted not to use a stock image and instead used one of my favourite photos – a ‘selfie’ taken by my grandfather in Glasgow, dated to 1900. I wonder when he was using the cutting-edge technology available to him in his time (a Kodak Box Brownie) whether he would have any idea of the technology available to his grandson?
